Objective:

To evaluate the efficacy and safety of EYP-1901 in patients with nonproliferative diabetic retinopathy (NPDR) over a 12-month period.

Key Findings:

• EYP-1901 showed promising early efficacy with stable or improved disease control at 12 months despite not meeting the primary endpoint.
• At 6 months, there was a statistically significant improvement in DRSS scores for patients treated with EYP-1901 compared to sham.
• The treatment effect diminished after approximately 9 months, indicating the implant's effect wore off by 12 months.
• The treatment was well tolerated with no new safety concerns reported.

Interpretation:

EYP-1901 demonstrates potential as a treatment for NPDR, with a notable duration of effect lasting around 9 months, suggesting the need for further investigation in larger trials.

Limitations:

• The trial did not achieve its primary endpoint of a 2-step-or-greater improvement on the DRSS.
• The treatment effect was not sustained beyond 9 months.

Conclusion:

EYP-1901 shows potential for disease control in NPDR, warranting further research in a planned phase 3 trial to confirm findings and optimize treatment duration.